SG121687A1 - Processes and intermediates for preparing anti-cancer compounds - Google Patents

Processes and intermediates for preparing anti-cancer compounds

Info

Publication number
SG121687A1
SG121687A1 SG200001746A SG200001746A SG121687A1 SG 121687 A1 SG121687 A1 SG 121687A1 SG 200001746 A SG200001746 A SG 200001746A SG 200001746 A SG200001746 A SG 200001746A SG 121687 A1 SG121687 A1 SG 121687A1
Authority
SG
Singapore
Prior art keywords
intermediates
processes
preparing anti
cancer compounds
cancer
Prior art date
Application number
SG200001746A
Other languages
English (en)
Inventor
Richard Shelton Lehner
Timothy Norris
Dinos Paul Santafianos
Original Assignee
Pfizer Prod Inc
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Osi Pharm Inc filed Critical Pfizer Prod Inc
Publication of SG121687A1 publication Critical patent/SG121687A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling
SG200001746A 1999-03-31 2000-03-27 Processes and intermediates for preparing anti-cancer compounds SG121687A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
SG121687A1 true SG121687A1 (en) 2006-05-26

Family

ID=22428179

Family Applications (2)

Application Number Title Priority Date Filing Date
SG200001746A SG121687A1 (en) 1999-03-31 2000-03-27 Processes and intermediates for preparing anti-cancer compounds
SG200302185A SG115536A1 (en) 1999-03-31 2000-03-27 Processes and intermediates for preparing anti-cancer compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG200302185A SG115536A1 (en) 1999-03-31 2000-03-27 Processes and intermediates for preparing anti-cancer compounds

Country Status (50)

Country Link
US (1) US6476040B1 (ru)
EP (1) EP1044969B1 (ru)
JP (2) JP3420549B2 (ru)
KR (2) KR100430210B1 (ru)
CN (2) CN100351242C (ru)
AP (2) AP1265A (ru)
AR (1) AR018705A1 (ru)
AT (1) ATE348098T1 (ru)
AU (2) AU781402B2 (ru)
BG (1) BG65194B1 (ru)
BR (1) BRPI0001486B8 (ru)
CA (2) CA2427221C (ru)
CO (1) CO5160273A1 (ru)
CR (1) CR6165A (ru)
CZ (1) CZ299426B6 (ru)
DE (1) DE60032275T2 (ru)
DK (1) DK1044969T3 (ru)
DZ (1) DZ3030A1 (ru)
EA (3) EA005892B1 (ru)
EE (1) EE04589B1 (ru)
EG (1) EG22506A (ru)
ES (1) ES2278578T3 (ru)
GE (1) GEP20022653B (ru)
GT (1) GT200000037A (ru)
HK (1) HK1029790A1 (ru)
HR (1) HRP20000182B1 (ru)
HU (1) HU227698B1 (ru)
ID (1) ID25427A (ru)
IL (2) IL168036A (ru)
IS (1) IS2468B (ru)
MA (1) MA25087A1 (ru)
MY (1) MY136270A (ru)
NO (2) NO321952B1 (ru)
NZ (2) NZ503683A (ru)
OA (1) OA11335A (ru)
PA (1) PA8491901A1 (ru)
PE (1) PE20001599A1 (ru)
PL (1) PL339330A1 (ru)
PT (1) PT1044969E (ru)
RS (1) RS49836B (ru)
SG (2) SG121687A1 (ru)
SK (1) SK287339B6 (ru)
SV (1) SV2002000047A (ru)
TN (1) TNSN00064A1 (ru)
TR (1) TR200000837A2 (ru)
TW (1) TW553939B (ru)
UA (2) UA70928C2 (ru)
UY (1) UY26086A1 (ru)
YU (1) YU13200A (ru)
ZA (1) ZA200001586B (ru)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (ru) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стойкий полиморф гидрохлорида n-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина, способ его получения (варианты) и фармацевтическое применение
MX242553B (es) 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
JP4703183B2 (ja) 2002-07-15 2011-06-15 シンフォニー エボルーション， インク． 受容体型キナーゼモジュレーターおよびその使用方法
US7148231B2 (en) 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US7618975B2 (en) 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
JP4795952B2 (ja) 2003-09-16 2011-10-19 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのキナゾリン誘導体
AU2004275842B2 (en) 2003-09-26 2010-09-02 Exelixis Inc. c-MET modulators and methods of use
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
RS52119B (en) * 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-phenylamino-HINAZOLIN-6-IL-STARCHES
CN101001629B (zh) 2004-09-17 2010-05-05 卫材R&D管理有限公司 药物组合物
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
WO2006090930A1 (ja) 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の新規併用
EP1925941B1 (en) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
EP1949902B1 (en) * 2005-11-07 2012-06-27 Eisai R&D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
WO2007061127A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
CN101547910A (zh) 2006-07-28 2009-09-30 合成纤维有限公司 结晶埃罗替尼
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
AU2008205847A1 (en) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
KR101445892B1 (ko) 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
US8349855B2 (en) * 2007-02-21 2013-01-08 Natco Pharma Limited Polymorphs of erlotinib hydrochloride and method of preparation
KR20140069232A (ko) 2007-04-04 2014-06-09 시플라 리미티드 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
WO2009002538A2 (en) * 2007-06-25 2008-12-31 Plus Chemicals S.A. Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
EP2162444B1 (en) 2007-07-11 2014-06-04 Hetero Drugs Limited An improved process for the preparation of erlotinib hydrochloride
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090131665A1 (en) * 2007-08-23 2009-05-21 Ales Gavenda Process for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCI
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
EP2218712B1 (en) 2007-11-09 2015-07-01 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
MX2010008187A (es) * 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Uso combinado de inhibidor de angiogenesis y taxano.
WO2009121042A1 (en) * 2008-03-28 2009-10-01 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
EP2307386A1 (en) * 2008-07-07 2011-04-13 Plus Chemicals S.A. Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
KR102187034B1 (ko) 2009-01-16 2020-12-04 엑셀리시스, 인코포레이티드 암 치료용 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2499118A2 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
RU2560683C2 (ru) 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
CN103124557A (zh) 2010-07-23 2013-05-29 基因里克斯(英国)有限公司 纯埃罗替尼
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
CN104755463A (zh) 2012-12-21 2015-07-01 卫材R&D管理有限公司 非晶态形式的喹啉衍生物及其生产方法
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
EP4089076A1 (en) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
CA2976325C (en) 2015-02-25 2023-07-04 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
KR20180018695A (ko) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 항암제
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436233A (en) * 1992-07-15 1995-07-25 Ono Pharmaceutical Co., Ltd. 4-aminoquinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
MX9707453A (es) * 1995-03-30 1997-12-31 Pfizer Derivados de quinazolina.
SI0880508T1 (en) 1996-02-13 2003-10-31 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
AU759691C (en) 1998-04-29 2004-04-29 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4- quinazolinamine mesylate anhydrate and monohydrate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436233A (en) * 1992-07-15 1995-07-25 Ono Pharmaceutical Co., Ltd. 4-aminoquinazoline derivatives
US5439895A (en) * 1992-07-15 1995-08-08 Ono Pharmaceutical Co., Ltd. 4-aminoquinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines

Also Published As

Publication number Publication date
EA200000274A2 (ru) 2000-10-30
DE60032275D1 (de) 2007-01-25
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
NO20001648D0 (no) 2000-03-30
AP1265A (en) 2004-03-26
HUP0001353A3 (en) 2002-01-28
BR0001486A (pt) 2001-05-02
KR100430209B1 (ko) 2004-05-03
UY26086A1 (es) 2000-10-31
IL135245A0 (en) 2001-05-20
CR6165A (es) 2008-10-10
JP3420549B2 (ja) 2003-06-23
DE60032275T2 (de) 2007-07-12
EA200000274A3 (ru) 2003-02-27
HU227698B1 (en) 2011-12-28
TR200000837A2 (tr) 2000-11-21
AU2005201494B2 (en) 2008-02-07
EA200201244A1 (ru) 2003-04-24
DZ3030A1 (fr) 2004-03-27
UA70928C2 (ru) 2004-11-15
NO321952B1 (no) 2006-07-24
JP4074509B2 (ja) 2008-04-09
CO5160273A1 (es) 2002-05-30
HU0001353D0 (en) 2000-06-28
MA25087A1 (fr) 2000-10-01
SV2002000047A (es) 2002-01-23
US6476040B1 (en) 2002-11-05
CA2427221A1 (en) 2000-09-30
CN100351242C (zh) 2007-11-28
ZA200001586B (en) 2001-10-01
EA005561B1 (ru) 2005-04-28
CA2427221C (en) 2008-09-16
SK287339B6 (sk) 2010-07-07
NO20054715L (no) 2000-10-02
OA11335A (en) 2003-12-10
JP2003176274A (ja) 2003-06-24
CZ20001155A3 (cs) 2001-03-14
KR20020084903A (ko) 2002-11-13
CA2302965A1 (en) 2000-09-30
JP2000290262A (ja) 2000-10-17
NZ512818A (en) 2003-01-31
EA004654B1 (ru) 2004-06-24
EP1044969B1 (en) 2006-12-13
PT1044969E (pt) 2007-05-31
IS2468B (is) 2008-12-15
GEP20022653B (en) 2002-03-25
KR100430210B1 (ko) 2004-05-03
RS49836B (sr) 2008-08-07
TW553939B (en) 2003-09-21
CN1699350A (zh) 2005-11-23
PL339330A1 (en) 2000-10-09
BG104278A (en) 2001-08-31
BRPI0001486B1 (pt) 2019-01-29
PE20001599A1 (es) 2001-01-18
EG22506A (en) 2003-03-31
EP1044969A2 (en) 2000-10-18
CA2302965C (en) 2004-02-17
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
AP1655A (en) 2006-09-01
EP1044969A3 (en) 2000-11-29
NO20001648L (no) 2000-10-02
EA200201245A1 (ru) 2003-04-24
AR018705A1 (es) 2001-11-28
ATE348098T1 (de) 2007-01-15
EA005892B1 (ru) 2005-06-30
UA80955C2 (en) 2007-11-26
GT200000037A (es) 2001-09-21
AU781402B2 (en) 2005-05-19
MY136270A (en) 2008-09-30
PA8491901A1 (es) 2001-12-14
SG115536A1 (en) 2005-10-28
HUP0001353A2 (hu) 2001-05-28
ID25427A (id) 2000-10-05
CN1276370A (zh) 2000-12-13
DK1044969T3 (da) 2007-04-23
KR20010014658A (ko) 2001-02-26
AU2005201494A1 (en) 2005-05-05
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
EE200000255A (et) 2000-12-15
NZ503683A (en) 2001-09-28
IS5411A (is) 2000-10-02
HK1029790A1 (en) 2001-04-12
HRP20000182A2 (en) 2001-04-30
ES2278578T3 (es) 2007-08-16
SK4442000A3 (en) 2000-10-09
EE04589B1 (et) 2006-02-15
CZ299426B6 (cs) 2008-07-23
BG65194B1 (bg) 2007-06-29
BRPI0001486B8 (pt) 2021-05-25
YU13200A (sh) 2002-10-18
CN1215061C (zh) 2005-08-17

Similar Documents

Publication Publication Date Title
EG22506A (en) Processes and intermediates for preparing anti-cancer compounds
AP2003002757A0 (en) Process and intermediates for preparing anticancer compounds
IL145798A0 (en) Fap-activated anti-tumor compounds
EP1140083A4 (en) NEW CONNECTIONS
HUP0200448A3 (en) Processes for preparing pesticidal intermediates
GB9930390D0 (en) Releasable fasteners
EG24063A (en) Novel compounds
IL149007A0 (en) Pentacyclic taxane compounds
GB9924855D0 (en) Novel processes
HUP0201401A2 (en) Processes for preparing pesticidal intermediates
GB0121486D0 (en) Processes for the preparation of Α-Aminoketones
HUP0202865A3 (en) Process for the preparation of 2-cyanopyridines
IL138691A (en) Process for the preparation of 3-acyl-indoles
GB9923024D0 (en) Lap top extension
HUP0000559A3 (en) Process for preparing cyanoaceticacidesters
EP1242378A4 (en) NEW PROCEDURES
TW382910U (en) Structural improvement for the physique of the clog
GB0001064D0 (en) Structure for positioning stationery
IL140300A0 (en) Process for the preparation of amides
HU9904575D0 (en) Process for preparation of n-alkoxy-methyl-acidamides
GB9930754D0 (en) Novel compounds
TW404191U (en) Structure improvement for pendants
TW377550U (en) Improvement for grass-planting brick
PL352099A1 (en) Process for the preparation of tetrafluorohalogenbenzenes
TW385647U (en) Structure for ring